Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses

15 June 2021 – Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity. Read full article

Alchemab wins Best Emerging Biotech Start-Up at OBN Awards

14 June 2021 – We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London. Read full article

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

15 December 2020 – Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is consistent across patients. Clonal expansion of the B cell population is also observed and may be the result of memory bystander effects. Read […]

Casting a spell: The Killer50 Magic Circle is unveiled

5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices. Read full article

Cambridge companies help develop Covid antibody cocktail

1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail. Read full article

Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool […]

UK-based Alchemab partners with Amii to accelerate the development of novel therapeutics to cure disease

29 September 2020 – Alchemab, a UK biotech company focused on harnessing the power of adaptive immune systems to cure disease, announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence. Read full article

Agile start-ups partner with academics to find COVID-19 solutions

16 July 2020 – Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19. Even before the lockdown began, Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans. These rapid innovations were achieved through collaborations with nearby experts, […]

Illumina unveils first Cambridge cohort for global genomics accelerator

23 June 2020 – Two Cambridge companies fly the flag for the UK cluster in the first global cohort of Illumina’s genomics accelerator. Alchemab Therapeutics and Tailor Bio are among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK. Read full article